Global α1 Adrenergic Agonist Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 α1 Adrenergic Agonist Market Overview

• 1.1 Product Overview and Scope of α1 Adrenergic Agonist
• 1.2 Classification of α1 Adrenergic Agonist by Types
  • 1.2.1 Global α1 Adrenergic Agonist Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global α1 Adrenergic Agonist Revenue Market Share by Types in 2018
  • 1.2.3 Phenylephrine
  • 1.2.4 Methoxamine
  • 1.2.5 Midodrine
  • 1.2.6 Oxymetazoline
• 1.3 Global α1 Adrenergic Agonist Market by Application
  • 1.3.1 Global α1 Adrenergic Agonist Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Paroxysmal Supraventricular Tachycardia
  • 1.3.3 Eye Drops
  • 1.3.4 Anaphylaxis
  • 1.3.5 Cardiac Arrest
  • 1.3.6 Anaphylaxis
  • 1.3.7 Cardiac Arrest
  • 1.3.8 Others
• 1.4 Global α1 Adrenergic Agonist Market by Regions
  • 1.4.1 Global α1 Adrenergic Agonist Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) α1 Adrenergic Agonist Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) α1 Adrenergic Agonist Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) α1 Adrenergic Agonist Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) α1 Adrenergic Agonist Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) α1 Adrenergic Agonist Status and Prospect (2014-2024)
• 1.5 Global Market Size of α1 Adrenergic Agonist (2014-2024)

2 Manufacturers Profiles

• 2.1 Bausch Health Companies
  • 2.1.1 Business Overview
  • 2.1.2 α1 Adrenergic Agonist Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Bausch Health Companies α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Pfizer
  • 2.2.1 Business Overview
  • 2.2.2 α1 Adrenergic Agonist Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Pfizer α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Sterling Winthrop
  • 2.3.1 Business Overview
  • 2.3.2 α1 Adrenergic Agonist Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Sterling Winthrop α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Sanofi
  • 2.4.1 Business Overview
  • 2.4.2 α1 Adrenergic Agonist Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Sanofi α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Paragon BioTeck
  • 2.5.1 Business Overview
  • 2.5.2 α1 Adrenergic Agonist Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Paragon BioTeck α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 West-Ward Pharmaceuticals
  • 2.6.1 Business Overview
  • 2.6.2 α1 Adrenergic Agonist Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 West-Ward Pharmaceuticals α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Biosyent Pharma
  • 2.7.1 Business Overview
  • 2.7.2 α1 Adrenergic Agonist Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Biosyent Pharma α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Novartis
  • 2.8.1 Business Overview
  • 2.8.2 α1 Adrenergic Agonist Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Novartis α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Omega Laboratories
  • 2.9.1 Business Overview
  • 2.9.2 α1 Adrenergic Agonist Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Omega Laboratories α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Medical Purchasing Solutions
  • 2.10.1 Business Overview
  • 2.10.2 α1 Adrenergic Agonist Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Medical Purchasing Solutions α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Avadel Legacy Pharmaceuticals
  • 2.11.1 Business Overview
  • 2.11.2 α1 Adrenergic Agonist Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Avadel Legacy Pharmaceuticals α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Amneal Biosciences
  • 2.12.1 Business Overview
  • 2.12.2 α1 Adrenergic Agonist Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Amneal Biosciences α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Cipla USA
  • 2.13.1 Business Overview
  • 2.13.2 α1 Adrenergic Agonist Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Cipla USA α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Par Pharmaceutical
  • 2.14.1 Business Overview
  • 2.14.2 α1 Adrenergic Agonist Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Par Pharmaceutical α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Glaxosmithkline
  • 2.15.1 Business Overview
  • 2.15.2 α1 Adrenergic Agonist Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Glaxosmithkline α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Teva
  • 2.16.1 Business Overview
  • 2.16.2 α1 Adrenergic Agonist Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Teva α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Bayer
  • 2.17.1 Business Overview
  • 2.17.2 α1 Adrenergic Agonist Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Bayer α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Impax Generics
  • 2.18.1 Business Overview
  • 2.18.2 α1 Adrenergic Agonist Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Impax Generics α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Mylan Pharmaceuticals
  • 2.19.1 Business Overview
  • 2.19.2 α1 Adrenergic Agonist Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Mylan Pharmaceuticals α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Physicians Total Care
  • 2.20.1 Business Overview
  • 2.20.2 α1 Adrenergic Agonist Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Physicians Total Care α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Merck
  • 2.21.1 Business Overview
  • 2.2.2 α1 Adrenergic Agonist Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Merck α1 Adrenergic Agonist Revenue, Gross Margin and Market Share (2017-2018)

3 Global α1 Adrenergic Agonist Market Competition, by Players

• 3.1 Global α1 Adrenergic Agonist Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 α1 Adrenergic Agonist Players Market Share
  • 3.2.2 Top 10 α1 Adrenergic Agonist Players Market Share
• 3.3 Market Competition Trend

4 Global α1 Adrenergic Agonist Market Size by Regions

• 4.1 Global α1 Adrenergic Agonist Revenue and Market Share by Regions
• 4.2 North America α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 4.3 Europe α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 4.5 South America α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)

5 North America α1 Adrenergic Agonist Revenue by Countries

• 5.1 North America α1 Adrenergic Agonist Revenue by Countries (2014-2019)
• 5.2 USA α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 5.3 Canada α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 5.4 Mexico α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)

6 Europe α1 Adrenergic Agonist Revenue by Countries

• 6.1 Europe α1 Adrenergic Agonist Revenue by Countries (2014-2019)
• 6.2 Germany α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 6.3 UK α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 6.4 France α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 6.5 Russia α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 6.6 Italy α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)

7 Asia-Pacific α1 Adrenergic Agonist Revenue by Countries

• 7.1 Asia-Pacific α1 Adrenergic Agonist Revenue by Countries (2014-2019)
• 7.2 China α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 7.3 Japan α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 7.4 Korea α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 7.5 India α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)

8 South America α1 Adrenergic Agonist Revenue by Countries

• 8.1 South America α1 Adrenergic Agonist Revenue by Countries (2014-2019)
• 8.2 Brazil α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 8.3 Argentina α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 8.4 Colombia α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue α1 Adrenergic Agonist by Countries

• 9.1 Middle East and Africa α1 Adrenergic Agonist Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 9.3 UAE α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 9.4 Egypt α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)
• 9.6 South Africa α1 Adrenergic Agonist Revenue and Growth Rate (2014-2019)

10 Global α1 Adrenergic Agonist Market Segment by Type

• 10.1 Global α1 Adrenergic Agonist Revenue and Market Share by Type (2014-2019)
• 10.2 Global α1 Adrenergic Agonist Market Forecast by Type (2019-2024)
• 10.3 Phenylephrine Revenue Growth Rate (2014-2024)
• 10.4 Methoxamine Revenue Growth Rate (2014-2024)
• 10.5 Midodrine Revenue Growth Rate (2014-2024)
• 10.6 Oxymetazoline Revenue Growth Rate (2014-2024)

11 Global α1 Adrenergic Agonist Market Segment by Application

• 11.1 Global α1 Adrenergic Agonist Revenue Market Share by Application (2014-2019)
• 11.2 α1 Adrenergic Agonist Market Forecast by Application (2019-2024)
• 11.3 Paroxysmal Supraventricular Tachycardia Revenue Growth (2014-2019)
• 11.4 Eye Drops Revenue Growth (2014-2019)
• 11.5 Anaphylaxis Revenue Growth (2014-2019)
• 11.6 Cardiac Arrest Revenue Growth (2014-2019)
• 11.7 Anaphylaxis Revenue Growth (2014-2019)
• 11.8 Cardiac Arrest Revenue Growth (2014-2019)
• 11.9 Others Revenue Growth (2014-2019)

12 Global α1 Adrenergic Agonist Market Size Forecast (2019-2024)

• 12.1 Global α1 Adrenergic Agonist Market Size Forecast (2019-2024)
• 12.2 Global α1 Adrenergic Agonist Market Forecast by Regions (2019-2024)
• 12.3 North America α1 Adrenergic Agonist Revenue Market Forecast (2019-2024)
• 12.4 Europe α1 Adrenergic Agonist Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific α1 Adrenergic Agonist Revenue Market Forecast (2019-2024)
• 12.6 South America α1 Adrenergic Agonist Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa α1 Adrenergic Agonist Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology